Drug Type Recombinant polypeptide, Biosimilar |
Synonyms- |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | CN | 13 Jun 2024 | |
Cardiovascular Diseases | Phase 3 | CN | 12 Jan 2023 | |
Obesity | IND Approval | CN | 05 Feb 2024 | |
Overweight | IND Approval | CN | 05 Feb 2024 |
Not Applicable | - | - | gsanaubpvt(fqkqppzkpt) = eerdpyvgkh yjqqkrefkp (glcixeuadq ) | - | 01 Jun 2021 | ||
gsanaubpvt(fqkqppzkpt) = epbiwumhdl yjqqkrefkp (glcixeuadq ) | |||||||
Not Applicable | - | - | kgufleyvpr(mpvxrwdkvm) = jcctgpejze bjpebxppqt (erpxggybus ) View more | - | 01 Jun 2021 | ||
kgufleyvpr(mpvxrwdkvm) = baayyvpjij bjpebxppqt (erpxggybus ) View more |